Joyce O’Shaughnessy

Aug 24, 2024 | cancernetwork.com | Joyce O’Shaughnessy |Janice Lu

BackgroundElacestrant the first oral selective estrogen receptor degrader (SERD) approved in estrogen receptor–positive ER+/HER2-negative (HER2–) advanced metastatic breast cancer that targets ESR1-mutated tumors.

Aug 18, 2024 | cancernetwork.com | Joyce O’Shaughnessy |Heather L. McArthur |Javier Cortés |Yeon Hee Park

BackgroundKEYNOTE-756 is a global phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo plus endocrine therapy (ET) in patients with early-stage high-risk estrogen receptor–positive (ER+)/HER2-negative breast cancer. Here, we report primary pathologic complete response (pCR) results and residual cancer burden (RCB) outcomes.

Aug 11, 2024 | cancernetwork.com | Stephanie Graff |Joyce O’Shaughnessy

BackgroundCurrent first-line standard of care for patients with metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (combined positive score [CPS] of 10 or greater) is pembrolizumab (Keytruda) plus chemotherapy (CT), but prognosis remains poor and new treatment options are needed.